Navigation Links
Novel immunotherapy drug receives FDA approval for the treatment of metastatic melanoma
Date:3/25/2011

New York, March 25, 2011 The US Food and Drug Administration announced today that the drug ipilimumab (brand name Yervoy) has been approved for the treatment of patients with metastatic melanoma. It is the first drug ever shown to improve overall survival for patients with advanced melanoma.

Ipilimumab uses a novel approach known as immunotherapy, which exploits the body's own immune system to attack cancer. The therapy, originally known as anti-CTLA-4, was developed in 1996 by James Allison, PhD, Chair of the Sloan-Kettering Institute's Immunology Program at MSKCC. For more than 20 years, Dr. Allison's research has focused on the mechanisms that regulate the immunologic responses of T lymphocytes commonly referred to as T cells with an emphasis on manipulating T cell response in order to develop novel tumor immunotherapy approaches.

Over the years, Memorial Sloan-Kettering researchers were deeply involved in preclinical and clinical studies using ipilimumab, most notably a 2009 phase II multicenter trial led by medical oncologist Jedd Wolchok, MD, PhD. Dr. Wolchok was a participant in the phase III trial, presented in 2010 at the American Society of Clinical Oncology annual meeting, which found a dose-response relationship to the drug in patients with stage III or IV disease. He also led a team in the development of a novel set of tumor-response criteria based on ipilimumab's unique mechanism of action.

Together, recent advances in understanding intracellular signaling pathways and immunotherapies such as ipilimumab to block those pathways have allowed clinicians to offer melanoma patients new treatment options for this disease.

"Ipilimumab is the first drug ever to be shown to produce an improvement in overall survival for patients with metastatic melanoma," according to Dr. Wolchok. "This is a significant achievement in a disease which has been so resistant to standard therapies. It is also a great source of hope for patients as we now build on the success of ipilimumab with novel combination therapies."

"The success of ipilimumab underscores the importance of basic research to clinical achievement," Dr. Allison added. "The concept came directly out of our studies on fundamental mechanisms of regulation of T cell responses."

In addition, researchers at the Center are studying biomarkers to help identify those patients who could benefit most from therapies like ipilimumab, and they have received a National Institutes of Health Grand Opportunity Stimulus award to study how the immune response to the NY-ESO-1 antigen is related to clinical outcome for ipilimumab therapy. This work, which is being conducted in several large clinical trials, is also supported by grants from the Melanoma Research Alliance and the Cancer Research Institute.

According to the National Cancer Institute, 68,130 new cases of melanoma were diagnosed in the United States in 2010, and 8,700 Americans died from the disease. Melanoma is the least common form of skin cancer, but is considered the most serious.


'/>"/>

Contact: Jeanne DAgostino
dagostij@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
2. A novel in vitro model for light-induced wound healing
3. Novel program translates behavioral and social science research into treatments to reduce obesity
4. Reovirus may be a novel approach to prostate cancer treatment
5. Novel stroke treatment passes safety stage of UCI-led clinical trial
6. Novel medical home program for pediatric patients, families cuts ER visits in half
7. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
8. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
9. Novel Method Eyed for Normalizing Blood Sugar
10. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
11. Novel nanoparticles prevent radiation damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
Breaking Medicine Technology: